<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain> Purpose: We retrospectively analyzed ABCG2 expression levels in patients with <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) to investigate the interaction between ABCG2 expression and the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> response to <z:chebi fb="0" ids="31941">oxaliplatin</z:chebi> and <z:chebi fb="0" ids="46345">5-fluorouracil</z:chebi> (FOLFOX). Methods: Forty-three patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> with <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> who received first-line FOLFOX treatment at our institution between 2008 and 2010 were enrolled </plain></SENT>
<SENT sid="1" pm="."><plain>ABCG2 expression was assessed by immunohistochemistry </plain></SENT>
<SENT sid="2" pm="."><plain><z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">Tumor</z:e> response was determined using the modified Response Evaluation Criteria in <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">Solid Tumors</z:e> criteria. Results: At least 50% <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> shrinkage was observed in 16/43 patients (37.2%), including a complete response in 1 patient </plain></SENT>
<SENT sid="3" pm="."><plain>According to the intensity of ABCG2 expression and the percentage of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells expressing ABCG2, 21 tumors displayed high ABCG2 expression </plain></SENT>
<SENT sid="4" pm="."><plain>Among these <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e>, only 2 (9.5%) exhibited partial responses to FOLFOX; conversely, 63.6% of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> with low ABCG2 expression (14/22) responded to FOLFOX </plain></SENT>
<SENT sid="5" pm="."><plain>Primary and corresponding metastatic samples were available for 15 patients, and 13 of the <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic tumors</z:e> had higher ABCG2 expression than the corresponding <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumors</z:e>, but only 1 of these <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> responded to FOLFOX (7.7%).  Conclusions: ABCG2 expression is associated with the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> response to FOLFOX in patients with metastatic <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>ABCG2 may be a selective marker for the efficacy of FOLFOX in treating <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
</text></document>